P-295 Azacytidine 75 mg/m2 ×5 day in high-risk myelodisplastic syndromes and acute myeloid leukemia refractory/relapsed patients

J. Bergua Burgués, M.J. Arcos, F. Carnicero, J. Prieto, C. Cabrera, M.L. Martín-Mateos, H. Fernandez, H. Bañas, F. Ibañez, C. Martín-Aguilera, R. Siguenza, N. Bermejo, M.J. García-Blanco, J. Sánchez
  • Leukemia Research, May 2013, Elsevier
  • DOI: 10.1016/s0145-2126(13)70342-4

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s0145-2126(13)70342-4

The following have contributed to this page: Dr Nuria Bermejo